David Scott Jones - 09 Feb 2024 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Role
SVP & Chief Commercial Officer
Signature
/s/ Ron Honig, Attorney-in-Fact
Issuer symbol
EYPT
Transactions as of
09 Feb 2024
Net transactions value
-$105,293
Form type
4
Filing time
13 Feb 2024, 17:38:56 UTC
Previous filing
05 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EYPT Common Stock Options Exercise $0 +4,967 +13% $0.000000 43,572 09 Feb 2024 Direct F1
transaction EYPT Common Stock Options Exercise $0 +5,000 +11% $0.000000 48,572 09 Feb 2024 Direct
transaction EYPT Common Stock Tax liability $56,304 -1,955 -4% $28.80 46,617 09 Feb 2024 Direct F2
transaction EYPT Common Stock Tax liability $48,989 -1,701 -3.6% $28.80 44,916 09 Feb 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EYPT Restricted Stock Units Options Exercise $0 -4,967 -100% $0.000000* 0 09 Feb 2024 Common Stock 4,967 $0.000000 Direct F3
transaction EYPT Restricted Stock Units Options Exercise $0 -5,000 -50% $0.000000 5,000 09 Feb 2024 Common Stock 5,000 $0.000000 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 643 shares acquired on January 31, 2024 pursuant to EyePoint's 2019 Employee Stock Purchase Plan.
F2 No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units
F3 The restricted stock units will vest in three ratable annual installments beginning February 9, 2022.
F4 The restricted stock units will vest in three ratable annual installments beginning February 9, 2023.